PTK2 and cancer: Currently, FAK kinase inhibitors are being vigorously developed for cancer treatment, and some of them have reached clinical trials targeting various malignant tumors.[23] However, kinase‐independent functions of FAK can't be suppressed by the kinase inhibitors.[24] Our study elucidates that FAISL specifically blocks FAK proteolysis and stabilizes FAK protein, indicating that FAISL may serve as a novel therapeutic target in the FAK pathway, which has the advantage of inhibiting both kinase‐dependent enzymatic function and kinase‐independent scaffolding function of FAK.